×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CLRB – cellectar biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CLRB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
02:03 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/16
10:55 am
clrb
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials [Yahoo! Finance]
Low
Report
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials [Yahoo! Finance]
12/11
12:54 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Low
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
12/10
05:00 pm
clrb
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
High
Report
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
12/5
09:05 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $13.00 price target on the stock.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $13.00 price target on the stock.
11/21
08:06 am
clrb
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]
Low
Report
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]
11/21
08:00 am
clrb
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
Low
Report
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
11/19
08:37 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
12/11
12:54 pm
Reiterates
Outperform
Market Perform
Oppenheimer Holdings Inc.
Low
Report
1.3%
Date
Time
Symbol
Headline
Impact
12/11
09:05 am
clrb
Form 8-K Cellectar Biosciences, For: Dec 10
High
Report
Form 8-K Cellectar Biosciences, For: Dec 10
11/18
07:15 am
clrb
Form 8-K Cellectar Biosciences, For: Nov 18
High
Report
Form 8-K Cellectar Biosciences, For: Nov 18
11/18
06:46 am
clrb
Form 10-Q Cellectar Biosciences, For: Sep 30
Medium
Report
Form 10-Q Cellectar Biosciences, For: Sep 30
11/15
04:34 pm
clrb
Form 8-K Cellectar Biosciences, For: Nov 15
Medium
Report
Form 8-K Cellectar Biosciences, For: Nov 15
11/14
04:55 pm
clrb
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Nantahala Capital Management, LLC
Medium
Report
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Nantahala Capital Management, LLC
11/14
04:48 pm
clrb
Form SC 13G/A Cellectar Biosciences, Filed by: ADAR1 Capital Management, LLC
Medium
Report
Form SC 13G/A Cellectar Biosciences, Filed by: ADAR1 Capital Management, LLC
11/14
01:27 pm
clrb
Form SC 13G/A Cellectar Biosciences, Filed by: LYTTON LAURENCE W
Low
Report
Form SC 13G/A Cellectar Biosciences, Filed by: LYTTON LAURENCE W
11/13
04:45 pm
clrb
Form NT 10-Q Cellectar Biosciences, For: Sep 30
Low
Report
Form NT 10-Q Cellectar Biosciences, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/10
Cellectar Biosciences Inc (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
17.5%
12/2 Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference 15.7%
5/15 CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma 11.5%
1/9 Form 8-K Cellectar Biosciences, For: Jan 09 8.9%
5/28 Form SC 13G Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 8.8%
10/15 Form 8-K Cellectar Biosciences, For: Oct 15 8.1%
2/14 Form SC 13G/A Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 7.5%
1/3 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock. 7.0%
2/25 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.6%
12/19 Cellectar Biosciences to Present at Biotech Showcase 2020 5.9%
12/2 Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference 15.7%
5/15 CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma 11.5%
1/9 Form 8-K Cellectar Biosciences, For: Jan 09 8.9%
5/28 Form SC 13G Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 8.8%
10/15 Form 8-K Cellectar Biosciences, For: Oct 15 8.1%
2/14 Form SC 13G/A Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 7.5%
1/3 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock. 7.0%
2/25 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.6%
12/19 Cellectar Biosciences to Present at Biotech Showcase 2020 5.9%
TOP News Decliners
7/9
Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
-26.9%
5/15 Form 8-K Cellectar Biosciences, For: May 15 -23.0%
2/19 Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study -20.9%
9/24 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma -17.5%
11/12 Form 8-K Cellectar Biosciences, For: Nov 12 -14.7%
5/13 Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma -12.6%
2/20 Form 8-K Cellectar Biosciences, For: Feb 19 -11.9%
3/17 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
3/9 Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update -7.9%
3/10 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
5/15 Form 8-K Cellectar Biosciences, For: May 15 -23.0%
2/19 Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study -20.9%
9/24 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma -17.5%
11/12 Form 8-K Cellectar Biosciences, For: Nov 12 -14.7%
5/13 Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma -12.6%
2/20 Form 8-K Cellectar Biosciences, For: Feb 19 -11.9%
3/17 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
3/9 Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update -7.9%
3/10 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: